✦ Soft Launch — We are a brand-new Foundation (incorporated September 2026). Our 501(c)(3) application is in progress. Spotted an error or have a question? Email us. ✦
← Foundation

Knowledge Bank

The Science Behind Schwannomatosis

Select a section to explore.

Shelved Research

Spider Venom & Pain

GsMTx-4 from tarantula venom targets the exact pain channel that SWN tumors activate. The most mechanistically precise compound ever tested in this disease. Proof of mechanism published. Funding gone.

  • GsMTx-4 — Piezo1 & Piezo2 inhibitor
  • Gutierrez et al. 2026 — proof of mechanism
  • Dooku1 — synthetic successor candidate
  • Researcher interview — August 2026
Read the story →
Genetics

Gene Profiles

What each SWN gene does, what goes wrong when it mutates, and what the clinical differences mean for patients — from diagnosis to treatment eligibility.

  • SMARCB1
  • LZTR1
  • NF2 — NF2-SWN
  • NEC — SWN-NEC — gene-negative
  • NOS — SWN-NOS — unclassified
Explore the genes →
Active & Recent

Clinical Trials

Trials actively recruiting SWN patients, plus recently closed studies awaiting or reviewing results. STARFISH and INTUITT-NF2 are open now.

  • INTUITT-NF2Recruiting
  • STARFISHRecruiting
  • TanezumabAwaiting Results
  • VistusertibCompleted 2019
View all trials →
Laboratory Research

Pre-Clinical Pipeline

The laboratory work behind schwannomatosis treatment — cell cultures, mouse models, zebrafish tanks. Where the science is, before it becomes a trial.

  • Hippo Pathway — YAP/TAZ
  • FAK — Focal Adhesion Kinase
  • Piezo1/Piezo2 — Mechanosensitive Channels
  • MEK/ERK Signaling
  • ErbB/HER Receptors (NF2-SWN)
  • Voltage-Gated Sodium Channels
Explore the pipeline →
Peer-Reviewed Literature

Referenced Papers

Every paper cited anywhere on this site — full citation, abstract, and direct links. When you see a statistic, this is where it comes from.

  • M et al. 2026 — Cancers
  • M et al. 2026 — Cells
  • I et al. 2026 — Translational Pediatrics
  • Y et al. 2026 — Advanced Science
View all papers →
2022 Consensus Standard

Terminology

Old names persist in records, insurance codes, and clinic notes for decades. Here is how the language changed and why it matters for your care.

  • Neurofibromatosis Type 2 → NF2-SWN
  • Neurofibromatosis Type 3 → Schwannomatosis (SWN)
  • Bilateral Acoustic Neurofibromatosis → NF2-SWN
  • NF2-Related Schwannomatosis → NF2-SWN
  • Schwannoma, acoustic, bilateral → NF2-SWN — vestibular schwannomas
See all corrections →
Conferences & Lectures

Video Library

Recorded presentations, clinical webinars, and patient voices — from NF Summits, CTF webinars, research conferences, and independent channels. Full transcripts available for expert lectures.

  • NF Summit 2026: We Are All Advocates - Catalyzing Experiences into Advocacy
  • NF Summit 2024: How We Study Pain in Neurofibromatosis and Schwannomatosis
  • NF Summit 2024: Improving Interpretation of Your Genetic Testing
  • NF2 and Schwannomatosis Webinar: Preclinical Models
Browse the library →
International & Emerging

Case Reports

Documented SWN cases from around the world — clinical case reports, international presentations, and unusual presentations that expand what we know about this disease.

  • In Progress Section being built — international cases incoming
  • Submit a case or citation via email
  • All languages accepted
  • Labeled clearly as case-level evidence
Learn more →
Auto-Updated Feed

Research News

Every new paper or article mentioning schwannomatosis or its genes — pulled automatically from PubMed and Google Alerts as they publish. No manual steps. No delay.

  • PubMed — peer-reviewed papers
  • Google Alerts — news & web
  • SMARCB1 · LZTR1 · NF2 · NEC · NOS
  • Updates automatically, daily
See the live feed →
✦

Help Fund the Next Discovery

The FIND Fund removes barriers between patients and the care they need. The Research Fund keeps scientists looking. When 501(c)(3) determination is complete, you will be able to direct your gift directly to research.

Connect With Us →